Price Alert

Amneal Pharmaceuticals In... (AMRX)

NASDAQ: AMRX · Real-Time Price · USD

9.40

0.00 (0.00%)

At close: Aug 14, 2025, 3:59 PM

9.39

-0.11%

Pre-market: Aug 15, 2025, 04:26 AM EDT

0.00% (1D)

Bid	9.06
Market Cap	2.95B
Revenue (ttm)	2.85B
Net Income (ttm)	3.38M
EPS (ttm)	0.01
PE Ratio (ttm)	940
Forward PE	9.48
Analyst	Buy

Ask	11.75
Volume	1,990,320
Avg. Volume (20D)	1,909,260.6
Open	9.31
Previous Close	9.40
Day's Range	9.15 - 9.41
52-Week Range	6.68 - 9.47
Beta	1.12

About AMRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AMRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Amneal Pharmaceuticals has released their quartely earnings on Aug 5, 2025:

Revenue of $725M misses estimates by $11.98M, with 3.31% YoY growth.

EPS of 0.25 exceeds estimates by 0.08, with 56.25% YoY growth.

Next Earnings Release

Amneal Pharmaceuticals Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+2.14%

Amneal Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 weeks ago

-0.25%

Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.

News

23 hours ago · zacks.com

Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 days ago · zacks.com

Here's Why Momentum in Amneal (AMRX) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...

1 week ago · fool.com

Amneal (AMRX) Q2 EPS Jumps 56%

1 week ago · seekingalpha.com

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investo...

1 week ago · zacks.com

Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

1 week ago · zacks.com

Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.

2 weeks ago · zacks.com

Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why

Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 weeks ago · zacks.com

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 weeks ago · zacks.com

Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?

Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Load More News